Open Access

PACAP and PAC1 receptor expression in pancreatic ductal carcinoma

  • Authors:
    • Sandor Ferencz
    • Dora Reglodi
    • Balint Kaszas
    • Attila Bardosi
    • Denes Toth
    • Zsofia Vekony
    • Viktoria Vicena
    • Oszkar Karadi
    • Dezso Kelemen
  • View Affiliations

  • Published online on: October 8, 2019     https://doi.org/10.3892/ol.2019.10971
  • Pages: 5725-5730
  • Copyright: © Ferencz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic carcinoma is one of the most malignant diseases and is associated with a poor survival rate. Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide that acts on three different G protein‑coupled receptors: the specific PAC1 and the VPAC1/2 that also bind vasoactive intestinal peptide. PACAP is widely distributed in the body and has diverse physiological effects. Among other things, it acts as a trophic factor and influences proliferation and differentiation of several different cells both under normal circumstances and tumourous transformation. Changes of PACAP and its receptors have been shown in various tumour types. However, it is not known whether PACAP and its specific receptor are altered in pancreatic cancer. Perioperative data of patients with pancreas carcinoma was investigated over a five‑year period. Histological results showed Grade 2 or Grade 3 adenocarcinoma in most cases. PACAP and PAC1 receptor expression were investigated by immunohistochemistry. Staining intensity of PAC1 receptor was strong in normal tissues both in the exocrine and endocrine parts of the pancreas, the receptor staining was markedly weaker in the adenocarcinoma. PACAP immunostaining was weak in the exocrine part and very strong in the islets and nerve elements in non‑tumourous tissues. The PACAP immunostaining almost disappeared in the adenocarcinoma samples. Based on these findings a decrease or lack of the PAC1 receptor/PACAP signalling might have an influence on tumour growth and/or differentiation.

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ferencz, S., Reglodi, D., Kaszas, B., Bardosi, A., Toth, D., Vekony, Z. ... Kelemen, D. (2019). PACAP and PAC1 receptor expression in pancreatic ductal carcinoma. Oncology Letters, 18, 5725-5730. https://doi.org/10.3892/ol.2019.10971
MLA
Ferencz, S., Reglodi, D., Kaszas, B., Bardosi, A., Toth, D., Vekony, Z., Vicena, V., Karadi, O., Kelemen, D."PACAP and PAC1 receptor expression in pancreatic ductal carcinoma". Oncology Letters 18.6 (2019): 5725-5730.
Chicago
Ferencz, S., Reglodi, D., Kaszas, B., Bardosi, A., Toth, D., Vekony, Z., Vicena, V., Karadi, O., Kelemen, D."PACAP and PAC1 receptor expression in pancreatic ductal carcinoma". Oncology Letters 18, no. 6 (2019): 5725-5730. https://doi.org/10.3892/ol.2019.10971